BIOCON BIOLOGICS Ogivri Trastuzumab Dkst Injection 150 mg **Refrigeration Required** (RX)

Ogivri Trastuzumab-Dkst Injection 150 mg is a medication used in the treatment of certain types of breast cancer and stomach cancer. It contains the active ingredient trastuzumab and belongs to a class of drugs known as monoclonal antibodies. It works by specifically targeting and blocking the action of a protein called HER2, which is overexpressed in some types of cancer cells. By blocking HER2, Ogivri helps to slow down or stop the growth and spread of cancer cells.

Ogivri Trastuzumab-Dkst Injection 150 mg is a type of cancer medication called a monoclonal antibody. It targets a protein called human epidermal growth factor receptor 2 (HER2) which is found on the surface of some cancer cells. By binding to HER2, Ogivri helps to slow down or stop the growth and spread of HER2-positive cancer cells.

Specifically, Ogivri works by blocking the action of HER2, which is involved in stimulating cell growth and division. This helps to slow down the growth of cancer cells and can potentially lead to their death. In addition, Ogivri also stimulates an immune response against the cancer cells, further aiding in their destruction.

Overall, by targeting HER2 and stimulating the immune system, Ogivri can help to treat certain types of breast and stomach cancers that overexpress this protein.